Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH): Tacrolimus Capsules Pass Generic Drug Quality and Therapeutic Equivalence Evaluation

Stock News09-29

Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that it has recently received the "Drug Supplemental Application Approval Notice" for tacrolimus capsules, issued by the National Medical Products Administration (NMPA). The company's tacrolimus capsules have successfully passed the generic drug quality and therapeutic equivalence evaluation.

Tacrolimus capsules are primarily indicated for preventing organ rejection following liver or kidney transplant procedures. They are also used to treat organ rejection after liver or kidney transplants when other immunosuppressive medications fail to provide adequate control. The original tacrolimus capsules were developed by Astellas Pharma Co. Limited.

Currently, the main domestic manufacturers of tacrolimus capsules in China include Zhejiang Hisun Pharmaceutical Co.,Ltd. and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114451118?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 15:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114451118","market":"sh","top_or_hot":-1,"title":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH): Tacrolimus Capsules Pass Generic Drug Quality and Therapeutic Equivalence Evaluation","media":"Stock News","content":"<p>Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that it has recently received the \"Drug Supplemental Application Approval Notice\" for tacrolimus capsules, issued by the National Medical Products Administration (NMPA). The company's tacrolimus capsules have successfully passed the generic drug quality and therapeutic equivalence evaluation.</p>\n<p>Tacrolimus capsules are primarily indicated for preventing organ rejection following liver or kidney transplant procedures. They are also used to treat organ rejection after liver or kidney transplants when other immunosuppressive medications fail to provide adequate control. The original tacrolimus capsules were developed by Astellas Pharma Co. Limited.</p>\n<p>Currently, the main domestic manufacturers of tacrolimus capsules in China include Zhejiang Hisun Pharmaceutical Co.,Ltd. and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH): Tacrolimus Capsules Pass Generic Drug Quality and Therapeutic Equivalence Evaluation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH): Tacrolimus Capsules Pass Generic Drug Quality and Therapeutic Equivalence Evaluation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-29 15:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that it has recently received the \"Drug Supplemental Application Approval Notice\" for tacrolimus capsules, issued by the National Medical Products Administration (NMPA). The company's tacrolimus capsules have successfully passed the generic drug quality and therapeutic equivalence evaluation.</p>\n<p>Tacrolimus capsules are primarily indicated for preventing organ rejection following liver or kidney transplant procedures. They are also used to treat organ rejection after liver or kidney transplants when other immunosuppressive medications fail to provide adequate control. The original tacrolimus capsules were developed by Astellas Pharma Co. Limited.</p>\n<p>Currently, the main domestic manufacturers of tacrolimus capsules in China include Zhejiang Hisun Pharmaceutical Co.,Ltd. and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600267","symbol_name":"海正药业","start_time":0,"source_url":"","article_id":"1114451118","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114451118","pubTimestamp":1759131908,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that it has recently received the \"Drug Supplemental Application Approval Notice\" for tacrolimus capsules, issued by the National Medical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600267":"海正药业","BK0028":"国家队","BK0239":"医药制造","BK0188":"融资融券","BK0060":"抗癌"},"translate_title":"浙江海正药业股份有限公司。（600267.SH）：他克莫司胶囊通过仿制药质量和治疗等效性评价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600267":1},"content_text":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that it has recently received the \"Drug Supplemental Application Approval Notice\" for tacrolimus capsules, issued by the National Medical Products Administration (NMPA). The company's tacrolimus capsules have successfully passed the generic drug quality and therapeutic equivalence evaluation.\nTacrolimus capsules are primarily indicated for preventing organ rejection following liver or kidney transplant procedures. They are also used to treat organ rejection after liver or kidney transplants when other immunosuppressive medications fail to provide adequate control. The original tacrolimus capsules were developed by Astellas Pharma Co. Limited.\nCurrently, the main domestic manufacturers of tacrolimus capsules in China include Zhejiang Hisun Pharmaceutical Co.,Ltd. and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114451118","isCrawlerRequest":true}